Genmab A/S Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer; Phase III Did Not Fulfill a Criterion; Independent Data Monitoring Committee Has Recommended That the Trial Should Continue to Enroll Patients

COPENHAGEN, Denmark, Jan. 5, 2009 (GLOBE NEWSWIRE) -- Genmab A/S (OMX:GEN) announced today that the interim survival analysis of the Phase III pivotal study investigating zalutumumab (HuMax-EGFr(R)) in refractory head and neck cancer patients did not fulfill a criterion for early stopping after half the trial has been completed.